Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platformTAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors. Los Altos, CA and Sydney, AU, July 20, 2023 – (ACN Newswire) – RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT…
Read More
